T1	Participants 90 150	AIDS patients in the Canadian randomized MAC treatment trial
T2	Participants 466 537	HIV-positive patients with Mycobacterium avium complex (MAC) bacteremia
T3	Participants 674 735	Twenty-four hospital-based HIV clinics in 16 Canadian cities.
